-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

Benzinga·09/24/2026 15:56:40
语音播报
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.